Work productivity among patients with metastatic breast cancer in the United States

References

• American Cancer Society. Cancer facts & figures 2021: American Cancer Society; 2021 [cited 2021 Nov 11]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf
   Google Scholar
• Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Female Breast Cancer National Cancer Institute: National Cancer Instutute; 2021 [cited 2021 Nov 11]. Available from: https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017;26(6):809–815. Epub 2017/05/20. PubMed PMID: 28522448; PubMed Central PMCID: PMCPMC5833304
   PubMed Web of Science ®Google Scholar
• Nekhlyudov L, Walker R, Ziebell R, et al. Cancer survivors’ experiences with insurance, finances, and employment: results from a multisite study.J Cancer Surviv. 2016;10(6):1104–1111. Epub 2016/11/04. PubMed PMID: 27277896
   PubMed Web of Science ®Google Scholar
• Yin W, Horblyuk R, and Perkins JJ, et al. Association between breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med. 2017;59(2):198–204.
   PubMed Web of Science ®Google Scholar
• Trogdon JG, Liu X, and Reeder-Hayes KE, et al. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.Cancer. 2020;126(18):4118–4125. Epub 2020/07/11. PubMed PMID: 32648979; PubMed Central PMCID: PMCPMC7721964
   PubMed Web of Science ®Google Scholar
• Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al. Cost of disease progression in patients with metastatic breast, lung, and colorectal cancer. Oncologist. 2019;24(9):1209–1218. Epub 2019/02/24. PubMed PMID: 30796156; PubMed Central PMCID: PMCPMC6738320
   PubMed Web of Science ®Google Scholar
• Masoud V, and Pages G. Targeted therapies in breast cancer: new challenges to fight against resistance.World J Clin Oncol. 2017;8(2):120–134. Epub 2017/04/26. PubMed PMID: 28439493; PubMed Central PMCID: PMCPMC5385433
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer v8. 2021 [cited 2021 Nov 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf
   Google Scholar
• US Food and Drug Administration. Palbociclib (IBRANCE) [cited 2021 Nov 5]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. Epub 2016/12/14. PubMed PMID: 27959613
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547. Epub 2018/05/03. PubMed PMID: 29718092
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. Epub 2017/10/03. PubMed PMID: 28968163
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. Epub 2018/06/05. PubMed PMID: 29860922
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. Epub 2016/03/08. PubMed PMID: 26947331
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. Epub 2017/06/06. PubMed PMID: 28580882
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Perjeta (Pertuzumab). [cited 2021 Nov 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf
   Google Scholar
• Capelan M, Pugliano L, De Azambuja E, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–282. Epub 2012/08/23. PubMed PMID: 22910839
   PubMed Web of Science ®Google Scholar
• IBM. IBM marketscan research databases IBM: IBM; 2021 [cited 2021 Nov 11]. Available from: https://www.ibm.com/products/marketscan-research-databases/databases
   Google Scholar
• Aizcorbe A, Liebman E, Pack S, et al. Measuring health care costs of individuals with employer-sponsored health insurance in the U.S.: a comparison of survey and claims data. Stat J IAOS. 2012;28(1–2):43–51. Epub 2012/01/01. PubMed PMID: 26146526; PubMed Central PMCID: PMCPMC4486327
   PubMedGoogle Scholar
• Hansen L. The Truven health marketscan databases for life sciences researchers 2017 [cited 2021 Nov 11]. Available from: https://docplayer.net/59862378-The-truven-health-marketscan-databases-for-life-sciences-researchers.html
   Google Scholar
• Princic N, Aizer A, Tang DH, et al. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Curr Med Res Opin. 2019;35(1):73–80.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. Epub 1987/01/01. PubMed PMID: 3558716
   PubMedGoogle Scholar
• Hanly P, Timmons A, Walsh PM, et al. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012;15(3):429–436.
   PubMed Web of Science ®Google Scholar
• U.S Bureau of Labor Statistics. Occupational employment statistics U.S Bureau of labor statistics: U.S Bureau of labor statistics. 2020 [cited 2021 Nov 11]. Available from: https://www.bls.gov/oes/current/oessrci.htm
   Google Scholar
• Bureau of Labor Statistics. Consumer Price Index (CPI). 2013 [cited 2021 Nov 11]. Available from: http://www.bls.gov/cpi/
   Google Scholar
• Arora S, Narayan P, Osgood CL, et al. U.S. FDA drug approvals for breast cancer - A decade in review. Clin Cancer Res. 2021. Epub 2021/10/30. PubMed PMID: 34711632
   Google Scholar
• Tripathy D, Curteis T, Hurvitz S, et al. Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2022;14:17588359221081203. Epub 2022/03/08. PubMed PMID: 35251320; PubMed Central PMCID: PMCPMC8891884.
   Web of Science ®Google Scholar
• Cleeland CS, Mayer M, Dreyer NA, et al. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: results from a substudy of the VIRGO observational cohort study. Breast. 2014;23(6):763–769. Epub 2014/09/07. PubMed PMID: 25193423
   PubMed Web of Science ®Google Scholar
• Rashid N, Koh HA, Baca HC, et al. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer Target Ther. 2016;8:173.
   PubMedGoogle Scholar
• Rocque GB, Williams CP, and Ingram SA, et al. Health care-related time costs in patients with metastatic breast cancer. Cancer Med. 2020;9(22):8423–8431. Epub 2020/09/22. PubMed PMID: 32955793; PubMed Central PMCID: PMCPMC7666754
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. 2014 [cited 2021 Nov 11]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast
   Google Scholar